# A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

> **NCT00481091** · PHASE1,PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 60 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** ABT-263

## Key facts

- **NCT ID:** NCT00481091
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-25
- **Primary completion:** 2022-05-12
- **Final completion:** 2022-05-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00481091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00481091, "A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00481091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*